The Impact of Enzyme-Replacement Therapy on Upper Airway Obstruction in Children with Mucopolysaccharidoses: Retrospective Cohort Study

Background. Data on the efficacy of enzyme replacement therapy (ERT) in relation to the pathology of ENT organs and respiratory performance in sleep in children with mucopolysaccharidosis (MPS) is poorly presented in the literature. Our aim was to assess the effect of ERT on the upper respiratory tract in children with MPS. Methods. According to the case histories, we studied treatment results of children with MPS type I and II who received ERT in the Research Center of Children’s Health from January 2007 to November 2016. The severity of upper airway obstruction and its change during ERT was assessed according to indices of apnea-hypopnea and desaturation (SpO2), average/minimal SpO2, duration of SpO2 episodes < 90%, and hypertrophy degree of palatine tonsils and adenoids. Results. The severity of the obstructive sleep apnea syndrome did not progress in children (n = 15) with MPS against the background of ERT with a median duration of 38 (23; 48) months: initially, the apnea-hypopnea index was 3 (1.3; 7.7), while the repeated study — 2.6 (0.9; 13.5) (p = 0.507). There was also no statistically significant change in cardiorespiratory monitoring values. Conclusion. Long-term ERT in children with MPS type I and II interferes with the progression of airway obstruction.

1. Berger KI, Fagondes SC, Giugliani R, et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis. 2013;36(2):201–210. doi: 10.1007/s10545-012-9555-1.

2. Barranger JA, Cabrera-Salazar MA, editors. Lysosomal storage disorders. Berlin: Springer; 2007.

3. Neufeld E, Muenzer J. The mucopolysaccharidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 2001. pp. 3421– 3452.

4. Clarke LA. Mucopolysaccharidosis Type I. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews [Internet]. Seattle (WA): University of Washington; 1993–2018. 2002 Oct 31 [updated 2016 Feb 11; сited 2018 Jan 15]. Available from: https:// www.ncbi.nlm.nih.gov/books/NBK1162/.

5. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267–277. doi: 10.1007/s00431-007-0635-4.

6. Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009;124(6):e1228–1239. doi: 10.1542/peds.2008-0999.

7. Lyon G, Kolodny EH, Pastores GM. Neurology of hereditary metabolic disease of children. 3rd ed. McGraw-Hill; 2006.

8. Scarpa M, Almassy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72. doi: 10.1186/1750-1172-6-72.

9. Krasnopol’skaya KD. Nasledstvennye bolezni obmena veshchestv. Spravochnoe posobie dlya vrachei. Moscow; 2005. (In Russ).

10. Keilmann A, Nakarat T, Bruce IA, et al. Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey. J Inherit Metab Dis. 2012;35(2):343–353. doi: 10.1007/ s10545-011-9378-5.

11. Gosudarstvennyi reestr lekarstvennykh sredstv. (In Russ).] Доступно по: http://www.grls.rosminzdrav.ru/grls.aspx. Ссылка активна на 01.03.2018.

12. Laraway S, Mercer J, Jameson E, et al. Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I. J Pediatr. 2016;178:219–226. doi: 10.1016/j. jpeds.2016.08.033.

13. Alcalde-Martin C, Muro-Tudelilla JM, Cancho-Candela R, et al. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS). Eur J Med Genet. 2010;53(6):371–377. doi: 10.1016/j.ejmg.2010.07.013.

14. Harmatz P, Yu ZF, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of longterm pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis. 2010;33(1):51–60. doi: 10.1007/s10545-009-9007-8.

15. Giugliani R, Lampe C, Guffon N, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) 10-year follow-up of patients who previously participated in an MPS VI Survey Study. Am J Med Genet A. 2014;164A(8):1953–1964. doi: 10.1002/ajmg.a.36584.

16. Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120(1):e37–46. doi: 10.1542/peds.2006-2156.

17. Tomanin R, Zanetti A, D’Avanzo F, et al. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years. Orphanet J Rare Dis. 2014;9:129. doi: 10.1186/ s13023-014-0129-1.

18. Horovitz DDG, Acosta AX, de Rosso Giuliani L, Ribeiro EM. Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: Six years follow-up of four children. Mol Genet Metab Rep. 2015;5:19–25. doi: 10.1016/j.ymgmr.2015.09.002.

19. de Carvalho Lopes J, Acosta AX, Terse-Ramos R. Polysomnographic characteristics of patients with mucopolysaccharidosis VI undergoing enzyme replacement therapy. J Sleep Med Disord. 2015;2(2):1016.

20. Osipova LA, Kuzenkova LM, Namazova-Baranova LS, et al. Efficacy and safety of enzyme replacement therapy in children with mucopolysaccharidosis type I, II, and VI: a single-center cohort study. Current pediatrics. 2018;17(1):76–84. (In Russ). doi: 10.15690/vsp.v17i1.1858.

21. Dehlink E, Tan HL. Update on paediatric obstructive sleep apnoea. J Thorac Dis. 2016;8(2):224–235. doi: 10.3978/j. issn.2072-1439.2015.12.04.

22. Dualibi AP, Martins AM, Moreira GA, et al. The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis. Braz J Otorhinolaryngol. 2016;82(5):522–528. doi: 10.1016/j.bjorl.2015.09.006.

23. Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123(1):229–240. doi: 10.1542/peds.2007-3847.

24. Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90(2):171–180. doi: 10.1016/j. ymgme.2006.08.007.

25. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329–337. doi: 10.1016/j.ymgme.2006.09.001.

26. Brands MM, Oussoren E, Ruijter GJ, et al. Up to five years experience with 11 mucopolysaccharidosis type VI patients. Mol Genet Metab. 2013;109(1):70–76. doi: 10.1016/j. ymgme.2013.02.013.